Back to Search Start Over

Design and preparation of proline, tryptophan and poly-l-lysine functionalized magnetic nanoparticles and their radiolabeling with 131 I and 177 Lu for potential theranostic use.

Authors :
Mirković M
Milanović Z
Perić M
Vranješ-Đurić S
Ognjanović M
Antić B
Kuraica M
Krstić I
Kubovcikova M
Antal I
Sobotova R
Zavisova V
Jurikova A
Fabian M
Koneracka M
Source :
International journal of pharmaceutics [Int J Pharm] 2022 Nov 25; Vol. 628, pp. 122288. Date of Electronic Publication: 2022 Oct 14.
Publication Year :
2022

Abstract

Surface modification of magnetic nanoparticles with poly-l-lysine, proline, and tryptophan was used to design potential theranostic agents for the application in cancer diagnosis and radionuclide-hyperthermia therapy. Characterization of bare and functionalized magnetic nanoparticles was performed in detail. The transparency of the examined magnetic nanoparticles was measured in the non-alternating magnetic field for a complete and better understanding of hyperthermia. For the first time amino acid-functionalized magnetic nanoparticles were labeled with theranostic radionuclides <superscript>131</superscript> I and <superscript>177</superscript> Lu. The specific absorption rate (SAR) procured for poly-l-lysine functionalized magnetic nanoparticles (SAR values of 99.7 W/g at H <subscript>0</subscript>  = 15.9 kA/m and resonant frequency of 252 kHz) demonstrated their possible application in magnetic hyperthermia. Poly-l-lysine functionalized magnetic nanoparticles labeled with <superscript>177</superscript> Lu showed the highest radiochemical purity (>99.00 %) and in vitro stability in saline and serum (>98.00 % up to 96 h). The in vivo analysis performed after their intravenous administration in healthy Wistar rats presented good in vivo stability for several days. Encouraging results as well as magnetic and radiochemical properties of <superscript>177</superscript> Lu-PLL-MNPs (80 °C) justify their further testing toward the potential use as theranostic agents for diagnostic and combined radionuclide-hyperthermia therapeutic applications.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2022 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-3476
Volume :
628
Database :
MEDLINE
Journal :
International journal of pharmaceutics
Publication Type :
Academic Journal
Accession number :
36252644
Full Text :
https://doi.org/10.1016/j.ijpharm.2022.122288